A Platform Study in Non-Small Cell Lung Cancer (NSCLC)

Study summary

The purpose of this study is to assess the safety and efficacy of multiple study interventions including novel-novel combinations or novel agents in combination with standard therapy for the treatment of metastatic NSCLC.

Ask AI to explain this study

Start here

Key things to know

Main goalTreatment

This describes the study’s primary purpose.

What is being studiedRilvegostomig and Cisplatin

Plus 5 other study approaches.

Who it may be forNon-small cell lung cancer (NSCLC) · Metastatic or stage IV

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Oct 1, 2026 · Source: ClinicalTrials.gov

Is enrollment open?Recruiting

The study is currently accepting participants.

What kind of study?Phase 1 / Phase 2

Interventional

Where is it offered?103 U.S. locations

Locations may change over time.

Who runs it?AstraZeneca

Study sponsor

Study overview

What this study is about

Purpose: Treatment
Study type: Interventional
Phase: Phase 1 / Phase 2
Sponsor: AstraZeneca
Interventions being studied: Drug: Rilvegostomig; Drug: Cisplatin; Drug: Carboplatin; Drug: Pemetrexed; Drug: Paclitaxel; Drug: Nab-paclitaxel; Drug: Ramucirumab

Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Cancer type

Non-small cell lung cancer (NSCLC)→

Disease setting

Metastatic or stage IV→

Treatment approach

Chemotherapy→

Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria

Participants with confirmed squamous or non-squamous NSCLC with a current Stage IV mNSCLC.
Provision of acceptable archival tumour tissue (or fresh tumour tissue biopsy if archival tumour tissue is not available and if clinically feasible) is mandatory at screening.
Measurable disease as defined by at least one lesion that can be accurately measured at baseline as ≥ 10 mm at the longest diameter.
Minimum life expectancy of 12 weeks in the opinion of the investigator.
Adequate organ and marrow function.
Contraceptive use by male or female participants should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
Adequate organ and marrow function. Inclusion Criteria for Sub Study 2:
Programmed death-ligand 1 (PD-L1) tumour proportion score (TPS) ≥ 1% (per local report).
Adequate coagulation and urinalysis.
Minimum body weight of 30 kg.

Reasons someone may not be able to joinExclusion criteria

Participants with epidermal growth factor receptor mutations, anaplastic lymphoma receptor fusions or any other known genomic alteration for which targeted therapy is approved in the first line per local standard of care.
Presence of small cell and neuroendocrine histology components.
Any severe or uncontrolled systemic diseases, including uncontrolled hypertension, and active bleeding diseases, ongoing or active known infection; interstitial lung disease/pneumonitis (of any grade); unstable and/or symptomatic venous thromboembolism, serious chronic gastrointestinal conditions associated with diarrhoea, active non-infectious skin disease or substance abuse.
Has had a prior stem cell, bone marrow, allogenic tissue, or solid organ transplant.
Has an active autoimmune disease that has required systemic treatment in the past 5 years.
History of clinically significant arrhythmia, cardiomyopathy of any aetiology or symptomatic congestive heart failure.
History of another primary malignancy except for malignancy treated with curative intent with no known active disease ≥ 2 years before the first dose of study intervention or presence of small cell and neuroendocrine histology components.
Persistent toxicities (common terminology criteria for adverse events \[CTCAE\] ≥ Grade 2) caused by previous anti-cancer therapy, excluding alopecia.
Spinal cord compression or symptomatic brain metastases.
Treatment with any other anti-cancer agents or immunosuppressive medication.
Palliative radiotherapy with a limited field of radiation within 2 weeks or with a wide field of radiation or to more than 30% of the bone marrow within 4 weeks, prior to the first dose of study intervention.

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

Study sites

U.S. locations

Research SitePhoenix, Arizona
Research SiteSanta Rosa, California
Research SiteJacksonville, Florida
Research SiteBaltimore, Maryland
Research SiteDetroit, Michigan
Research SiteRochester, Minnesota
Research SiteCleveland, Ohio
Research SiteProvidence, Rhode Island
Research SiteProvidence, Rhode Island
Research SiteTyler, Texas
Research SiteAnderlecht
Research SiteHasselt

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Oct 1, 2026. Always confirm current availability with the study team.

View original record ↗